Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes two Insilico-Menarini Group deals: a 2023 license for ISM5043, a KAT6 inhibitor for ER+/HER2- breast cancer (partnered with Stemline Therapeutics), valued at $12 million upfront plus up to $150 million in development/regulatory milestones and up to $344 million in sales milestones; and a 2024 agreement for an undisclosed preclinical small-molecule solid-tumor program, with total potential value over $550 million and a $20 million upfront payment — consistent with the ">$500M" figure in the old description.

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.